fizer Inc announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) approved a new four-dose, multi-dose vial (MDV) presentation of Prevenar 13®* (pneumococcal polysaccharide conjugate vaccine [13 – valent, adsorbed]). This new MDV presentation was developed to help maximize efficiency for health care workers by helping to significantly reduce storage requirements and shipping costs in communities with health systems that are still developing.
The MDV presentation of Prevenar 13® offers significant benefits to developing countries, including a 75 percent reduction in:
• Temperature-controlled supply chain requirements,
• United Nations Children’s Fund (UNICEF) shipping costs, and
• Storage requirements at the national, regional, district, and community levels.